WO2001055306A3 - Nucleic acids, proteins, and antibodies - Google Patents

Nucleic acids, proteins, and antibodies Download PDF

Info

Publication number
WO2001055306A3
WO2001055306A3 PCT/US2001/001304 US0101304W WO0155306A3 WO 2001055306 A3 WO2001055306 A3 WO 2001055306A3 US 0101304 W US0101304 W US 0101304W WO 0155306 A3 WO0155306 A3 WO 0155306A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
antibodies
further relates
present
novel
Prior art date
Application number
PCT/US2001/001304
Other languages
French (fr)
Other versions
WO2001055306A2 (en
WO2001055306A8 (en
Inventor
Craig A Rosen
Steven C Barash
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven C Barash
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven C Barash, Steven M Ruben filed Critical Human Genome Sciences Inc
Priority to EP01946887A priority Critical patent/EP1254165A2/en
Priority to AU2001257912A priority patent/AU2001257912A1/en
Publication of WO2001055306A2 publication Critical patent/WO2001055306A2/en
Publication of WO2001055306A8 publication Critical patent/WO2001055306A8/en
Publication of WO2001055306A3 publication Critical patent/WO2001055306A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723Cationic antimicrobial peptides, e.g. defensins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
PCT/US2001/001304 2000-01-31 2001-01-17 Nucleic acids, proteins, and antibodies WO2001055306A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01946887A EP1254165A2 (en) 2000-01-31 2001-01-17 Nucleic acids, proteins, and antibodies
AU2001257912A AU2001257912A1 (en) 2000-01-31 2001-01-17 Nucleic acids, proteins, and antibodies

Applications Claiming Priority (235)

Application Number Priority Date Filing Date Title
US17906500P 2000-01-31 2000-01-31
US60/179,065 2000-01-31
US18062800P 2000-02-04 2000-02-04
US60/180,628 2000-02-04
US18466400P 2000-02-24 2000-02-24
US60/184,664 2000-02-24
US18635000P 2000-03-02 2000-03-02
US60/186,350 2000-03-02
US18987400P 2000-03-16 2000-03-16
US60/189,874 2000-03-16
US19007600P 2000-03-17 2000-03-17
US60/190,076 2000-03-17
US19812300P 2000-04-18 2000-04-18
US60/198,123 2000-04-18
US20551500P 2000-05-19 2000-05-19
US60/205,515 2000-05-19
US20946700P 2000-06-07 2000-06-07
US60/209,467 2000-06-07
US21488600P 2000-06-28 2000-06-28
US60/214,886 2000-06-28
US21513500P 2000-06-30 2000-06-30
US60/215,135 2000-06-30
US21688000P 2000-07-07 2000-07-07
US21664700P 2000-07-07 2000-07-07
US60/216,880 2000-07-07
US60/216,647 2000-07-07
US21749600P 2000-07-11 2000-07-11
US21748700P 2000-07-11 2000-07-11
US60/217,487 2000-07-11
US60/217,496 2000-07-11
US21829000P 2000-07-14 2000-07-14
US60/218,290 2000-07-14
US22096400P 2000-07-26 2000-07-26
US22096300P 2000-07-26 2000-07-26
US60/220,964 2000-07-26
US60/220,963 2000-07-26
US22575900P 2000-08-14 2000-08-14
US22451800P 2000-08-14 2000-08-14
US22526800P 2000-08-14 2000-08-14
US22575700P 2000-08-14 2000-08-14
US22451900P 2000-08-14 2000-08-14
US22544700P 2000-08-14 2000-08-14
US22526600P 2000-08-14 2000-08-14
US22521400P 2000-08-14 2000-08-14
US22575800P 2000-08-14 2000-08-14
US22521300P 2000-08-14 2000-08-14
US22526700P 2000-08-14 2000-08-14
US22527000P 2000-08-14 2000-08-14
US60/225,757 2000-08-14
US60/225,213 2000-08-14
US60/225,267 2000-08-14
US60/225,759 2000-08-14
US60/225,214 2000-08-14
US60/225,266 2000-08-14
US60/225,758 2000-08-14
US60/225,268 2000-08-14
US60/225,447 2000-08-14
US60/224,518 2000-08-14
US60/225,270 2000-08-14
US60/224,519 2000-08-14
US22627900P 2000-08-18 2000-08-18
US60/226,279 2000-08-18
US22686800P 2000-08-22 2000-08-22
US22668100P 2000-08-22 2000-08-22
US22718200P 2000-08-22 2000-08-22
US60/226,681 2000-08-22
US60/226,868 2000-08-22
US60/227,182 2000-08-22
US22700900P 2000-08-23 2000-08-23
US60/227,009 2000-08-23
US22892400P 2000-08-30 2000-08-30
US60/228,924 2000-08-30
US22934500P 2000-09-01 2000-09-01
US22928700P 2000-09-01 2000-09-01
US22934300P 2000-09-01 2000-09-01
US22934400P 2000-09-01 2000-09-01
US60/229,343 2000-09-01
US60/229,344 2000-09-01
US60/229,345 2000-09-01
US60/229,287 2000-09-01
US22951300P 2000-09-05 2000-09-05
US22950900P 2000-09-05 2000-09-05
US60/229,513 2000-09-05
US60/229,509 2000-09-05
US23043800P 2000-09-06 2000-09-06
US23043700P 2000-09-06 2000-09-06
US60/230,437 2000-09-06
US60/230,438 2000-09-06
US23124400P 2000-09-08 2000-09-08
US23141300P 2000-09-08 2000-09-08
US23124200P 2000-09-08 2000-09-08
US23208000P 2000-09-08 2000-09-08
US23208100P 2000-09-08 2000-09-08
US23124300P 2000-09-08 2000-09-08
US23141400P 2000-09-08 2000-09-08
US60/231,413 2000-09-08
US60/231,414 2000-09-08
US60/232,080 2000-09-08
US60/232,081 2000-09-08
US60/231,244 2000-09-08
US60/231,243 2000-09-08
US60/231,242 2000-09-08
US23196800P 2000-09-12 2000-09-12
US60/231,968 2000-09-12
US23240000P 2000-09-14 2000-09-14
US23239900P 2000-09-14 2000-09-14
US23306300P 2000-09-14 2000-09-14
US23306400P 2000-09-14 2000-09-14
US23306500P 2000-09-14 2000-09-14
US23239800P 2000-09-14 2000-09-14
US23240100P 2000-09-14 2000-09-14
US23239700P 2000-09-14 2000-09-14
US60/232,398 2000-09-14
US60/232,397 2000-09-14
US60/233,064 2000-09-14
US60/233,063 2000-09-14
US60/232,400 2000-09-14
US60/232,401 2000-09-14
US60/233,065 2000-09-14
US60/232,399 2000-09-14
US23422300P 2000-09-21 2000-09-21
US23427400P 2000-09-21 2000-09-21
US60/234,223 2000-09-21
US60/234,274 2000-09-21
US23499800P 2000-09-25 2000-09-25
US23499700P 2000-09-25 2000-09-25
US60/234,998 2000-09-25
US60/234,997 2000-09-25
US23548400P 2000-09-26 2000-09-26
US60/235,484 2000-09-26
US23583600P 2000-09-27 2000-09-27
US23583400P 2000-09-27 2000-09-27
US60/235,834 2000-09-27
US60/235,836 2000-09-27
US23636800P 2000-09-29 2000-09-29
US23636900P 2000-09-29 2000-09-29
US23636700P 2000-09-29 2000-09-29
US23632700P 2000-09-29 2000-09-29
US23637000P 2000-09-29 2000-09-29
US60/236,368 2000-09-29
US60/236,369 2000-09-29
US60/236,367 2000-09-29
US60/236,370 2000-09-29
US60/236,327 2000-09-29
US23703800P 2000-10-02 2000-10-02
US23680200P 2000-10-02 2000-10-02
US23703700P 2000-10-02 2000-10-02
US23703900P 2000-10-02 2000-10-02
US23704000P 2000-10-02 2000-10-02
US60/236,802 2000-10-02
US60/237,039 2000-10-02
US60/237,037 2000-10-02
US60/237,040 2000-10-02
US60/237,038 2000-10-02
US23993700P 2000-10-13 2000-10-13
US23993500P 2000-10-13 2000-10-13
US60/239,935 2000-10-13
US60/239,937 2000-10-13
US24096000P 2000-10-20 2000-10-20
US24178500P 2000-10-20 2000-10-20
US24180900P 2000-10-20 2000-10-20
US24178600P 2000-10-20 2000-10-20
US24178700P 2000-10-20 2000-10-20
US24180800P 2000-10-20 2000-10-20
US24182600P 2000-10-20 2000-10-20
US24122100P 2000-10-20 2000-10-20
US60/240,960 2000-10-20
US60/241,221 2000-10-20
US60/241,826 2000-10-20
US60/241,786 2000-10-20
US60/241,787 2000-10-20
US60/241,808 2000-10-20
US60/241,809 2000-10-20
US60/241,785 2000-10-20
US24461700P 2000-11-01 2000-11-01
US60/244,617 2000-11-01
US24647400P 2000-11-08 2000-11-08
US24652600P 2000-11-08 2000-11-08
US24652800P 2000-11-08 2000-11-08
US24652700P 2000-11-08 2000-11-08
US24647500P 2000-11-08 2000-11-08
US24647700P 2000-11-08 2000-11-08
US24647600P 2000-11-08 2000-11-08
US24652500P 2000-11-08 2000-11-08
US24653200P 2000-11-08 2000-11-08
US24652300P 2000-11-08 2000-11-08
US24652400P 2000-11-08 2000-11-08
US60/246,475 2000-11-08
US60/246,613 2000-11-08
US60/246,609 2000-11-08
US60/246,477 2000-11-08
US60/246,476 2000-11-08
US60/246,610 2000-11-08
US60/246,478 2000-11-08
US60/246,474 2000-11-08
US60/246,525 2000-11-08
US60/246,524 2000-11-08
US60/246,528 2000-11-08
US60/246,523 2000-11-08
US60/246,527 2000-11-08
US60/246,611 2000-11-08
US60/246,526 2000-11-08
US60/246,532 2000-11-08
US60/249,207 2000-11-17
US60/249,297 2000-11-17
US60/249,214 2000-11-17
US60/249,211 2000-11-17
US60/249,215 2000-11-17
US60/249,217 2000-11-17
US60/249,300 2000-11-17
US60/249,265 2000-11-17
US60/249,213 2000-11-17
US60/249,216 2000-11-17
US60/249,209 2000-11-17
US60/249,212 2000-11-17
US60/249,299 2000-11-17
US60/249,264 2000-11-17
US60/249,210 2000-11-17
US60/249,244 2000-11-17
US60/249,218 2000-11-17
US60/249,245 2000-11-17
US60/249,208 2000-11-17
US60/250,391 2000-12-01
US60/250,160 2000-12-01
US60/251,030 2000-12-05
US60/256,719 2000-12-05
US60/251,988 2000-12-05
US60/251,479 2000-12-06
US60/251,868 2000-12-08
US60/251,856 2000-12-08
US60/251,869 2000-12-08
US60/251,989 2000-12-08
US60/251,990 2000-12-08
US60/254,097 2000-12-11
US60/259,678 2001-01-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/190,268 Continuation-In-Part US8408420B2 (en) 2010-07-23 2011-07-25 Lifting and rotating water reservoir with attached water bottle for dispensing of water from water cooler

Publications (3)

Publication Number Publication Date
WO2001055306A2 WO2001055306A2 (en) 2001-08-02
WO2001055306A8 WO2001055306A8 (en) 2001-09-07
WO2001055306A3 true WO2001055306A3 (en) 2001-12-20

Family

ID=27587114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001304 WO2001055306A2 (en) 2000-01-31 2001-01-17 Nucleic acids, proteins, and antibodies

Country Status (2)

Country Link
CA (1) CA2395811A1 (en)
WO (1) WO2001055306A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CA2813466A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR102014061B1 (en) 2011-10-03 2019-08-28 모더나 세라퓨틱스, 인코포레이티드 Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
LT2791160T (en) 2011-12-16 2022-06-10 Modernatx, Inc. Modified mrna compositions
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
AU2013243947A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
EP3578652B1 (en) 2013-03-15 2023-07-12 ModernaTX, Inc. Ribonucleic acid purification
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
HUE056760T2 (en) 2013-07-11 2022-03-28 Modernatx Inc Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
MX2016004249A (en) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor.
EP3157573A4 (en) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CA2955238A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Circular polynucleotides
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
CN108438819B (en) * 2018-04-19 2024-03-26 海盐明盛塑业有限公司 Plastic bottle positioning, conveying and sealing device

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 20 September 2000 (2000-09-20), "NIH-MGC. Gene sequence", XP002945764, Database accession no. BE793657 *
DATABASE GENBANK [online] XIA ET AL.: "Cloning expression of molecules homologous to HNK-1 sulfotransferase", XP002945763, Database accession no. AJ289131 *
GENE SEQUENCE, 19 May 2000 (2000-05-19) *

Also Published As

Publication number Publication date
WO2001055306A2 (en) 2001-08-02
WO2001055306A8 (en) 2001-09-07
CA2395811A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
WO2001055328A8 (en) Nucleic acids, proteins, and antibodies
WO2001090304A3 (en) Nucleic acids, proteins, and antibodies
WO2001054472A8 (en) Nucleic acids, proteins, and antibodies
WO2001055306A8 (en) Nucleic acids, proteins, and antibodies
WO2001055326A3 (en) Nucleic acids, proteins, and antibodies
WO2002026930A3 (en) Nucleic acids, proteins, and antibodies
WO2001055440A8 (en) Nucleic acids, proteins, and antibodies
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
WO2002072763A3 (en) Nucleic acids, proteins, and antibodies
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies
WO2001055449A8 (en) Nucleic acids, proteins, and antibodies
WO2001055305A3 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 31/2001 UNDER "PUBLISHED", ADD "WITH SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU."

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2395811

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001946887

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001946887

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001946887

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)